{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:13:56Z","timestamp":1791486836632,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.intimp.2022.109442","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T15:53:19Z","timestamp":1669218799000},"page":"109442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"PB","title":["Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition"],"prefix":"10.1016","volume":"113","author":[{"given":"Pornpimon","family":"Yuti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupanun","family":"Wutti-in","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunghathai","family":"Sawasdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katesara","family":"Kongkhla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nattaporn","family":"Phanthaphol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kornkan","family":"Choomee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thaweesak","family":"Chieochansin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aussara","family":"Panya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutita","family":"Junking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pa-thai","family":"Yenchitsomanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatuporn","family":"Sujjitjoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.intimp.2022.109442_b0005","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrc1589","article-title":"Mechanisms of B-cell lymphoma pathogenesis","volume":"5","author":"Kuppers","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.intimp.2022.109442_b0010","doi-asserted-by":"crossref","DOI":"10.1177\/1176935119835538","article-title":"Predicting Outcomes in Patients With Diffuse Large B-Cell Lymphoma Treated With Standard of Care","volume":"18","author":"Galaznik","year":"2019","journal-title":"Cancer Inform."},{"issue":"1","key":"10.1016\/j.intimp.2022.109442_b0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2015.213","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study","volume":"51","author":"Van Den Neste","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.intimp.2022.109442_b0020","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3389\/fonc.2020.01594","article-title":"Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions","volume":"10","author":"Greenbaum","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2022.109442_b0025","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3389\/fonc.2018.00351","article-title":"Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma","volume":"8","author":"Zhang","year":"2018","journal-title":"Front. Oncol."},{"issue":"16","key":"10.1016\/j.intimp.2022.109442_b0030","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.intimp.2022.109442_b0035","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1078-0432.CCR-18-2743","article-title":"FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma","volume":"25","author":"Bouchkouj","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.intimp.2022.109442_b0040","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10254","key":"10.1016\/j.intimp.2022.109442_b0045","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.intimp.2022.109442_b0050","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2022.109442_b0055","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol."},{"key":"10.1016\/j.intimp.2022.109442_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: Elements and their synergistic function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine."},{"issue":"2","key":"10.1016\/j.intimp.2022.109442_b0065","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.intimp.2022.109442_b0070","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00262-020-02838-8","article-title":"CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors","volume":"70","author":"Chen","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.intimp.2022.109442_b0075","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/blood-2011-03-344275","article-title":"CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo","volume":"119","author":"Song","year":"2012","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.intimp.2022.109442_b0080","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2020.38.15_suppl.3012","article-title":"Long-term follow-up of anti-CD19 CAR T-cell therapy for B-cell lymphoma and chronic lymphocytic leukemia","volume":"38","author":"Cappell","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2022.109442_b0085","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3389\/fcell.2020.00803","article-title":"Augmenting the Effectiveness of CAR-T Cells by Enhanced Self-Delivery of PD-1-Neutralizing scFv","volume":"8","author":"Ping","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"12","key":"10.1016\/j.intimp.2022.109442_b0090","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2022.109442_b0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.564099","article-title":"Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109442_b0100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10549-020-06032-3","article-title":"Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy","volume":"186","author":"Luangwattananun","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.intimp.2022.109442_b0105","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.657868","article-title":"Chimeric Antigen Receptor T Cells Targeting Integrin alphavbeta6 Expressed on Cholangiocarcinoma Cells","volume":"11","author":"Phanthaphol","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109442_b0110","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.1038\/s41598-021-85747-9","article-title":"Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma","volume":"11","author":"Supimon","year":"2021","journal-title":"Sci. Rep."},{"issue":"Pt B","key":"10.1016\/j.intimp.2022.109442_b0115","article-title":"Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells","volume":"89","author":"Sangsuwannukul","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2022.109442_b0120","first-page":"11","article-title":"Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains. Frontiers","author":"Wutti-in","year":"2022","journal-title":"Oncology."},{"issue":"3","key":"10.1016\/j.intimp.2022.109442_b0125","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2022.109442_b0130","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/mt.2016.63","article-title":"GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade","volume":"24","author":"Gargett","year":"2016","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2022.109442_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100971","article-title":"GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma - assessing tumor and T cell interaction","volume":"14","author":"Sujjitjoon","year":"2021","journal-title":"Transl. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109442_b0140","doi-asserted-by":"crossref","first-page":"10813","DOI":"10.1038\/s41598-017-11052-z","article-title":"Cytotoxic response against Epstein Barr virus coexists with diffuse large B-cell lymphoma tolerogenic microenvironment: clinical features and survival impact","volume":"7","author":"Cohen","year":"2017","journal-title":"Sci. Rep."},{"issue":"25","key":"10.1016\/j.intimp.2022.109442_b0145","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.intimp.2022.109442_b0150","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.intimp.2022.109442_b0155","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-10-2660","article-title":"Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells","volume":"17","author":"Andorsky","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.intimp.2022.109442_b0160","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13225827","article-title":"Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions","volume":"13","author":"Modi","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.intimp.2022.109442_b0165","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(19)30693-X","article-title":"Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1\u20132 study","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet Oncol."},{"issue":"23","key":"10.1016\/j.intimp.2022.109442_b0170","doi-asserted-by":"crossref","first-page":"34341","DOI":"10.18632\/oncotarget.9114","article-title":"Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model","volume":"7","author":"Suarez","year":"2016","journal-title":"Oncotarget."},{"issue":"9","key":"10.1016\/j.intimp.2022.109442_b0175","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.intimp.2022.109442_b0180","first-page":"1","article-title":"Co-expression of PD-L1 Antibodies Enhances the Anti-Tumor Efficacy of Chimeric Antigen Receptor T Cells","volume":"5","author":"Lal","year":"2019","journal-title":"J. Cancer Res. Immuno-oncology."},{"issue":"22","key":"10.1016\/j.intimp.2022.109442_b0185","doi-asserted-by":"crossref","first-page":"6982","DOI":"10.1158\/1078-0432.CCR-17-0867","article-title":"Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors","volume":"23","author":"Li","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2022.109442_b0190","doi-asserted-by":"crossref","first-page":"11472","DOI":"10.1038\/s41598-019-47910-1","article-title":"Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1\/PD-L1 signaling","volume":"9","author":"De Sousa","year":"2019","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.intimp.2022.109442_b0195","article-title":"Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. JCI","volume":"5","author":"Bar","year":"2020","journal-title":"Insight."},{"issue":"6","key":"10.1016\/j.intimp.2022.109442_b0200","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004400","article-title":"PD-L1 blockade restores CAR T cell activity through IFN-gamma-regulation of CD163+ M2 macrophages","volume":"10","author":"Yamaguchi","year":"2022","journal-title":"J. ImmunoTher. Cancer"},{"issue":"26","key":"10.1016\/j.intimp.2022.109442_b0205","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.intimp.2022.109442_b0210","first-page":"3382","article-title":"Significance of PD-L1 in the diagnosis and treatment of B-cell malignant lymphoma","volume":"17","author":"Yang","year":"2019","journal-title":"Oncol Lett."},{"issue":"5","key":"10.1016\/j.intimp.2022.109442_b0215","doi-asserted-by":"crossref","first-page":"622","DOI":"10.4161\/cbt.7.5.5689","article-title":"Clinical significance of B7\u2013H1 (PD-L1) expression in human acute leukemia","volume":"7","author":"Chen","year":"2008","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2022.109442_b0220","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4049\/jimmunol.1800129","article-title":"IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells","volume":"201","author":"Xiao","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.109442_b0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2017.10.001","article-title":"Expression of checkpoint molecules on myeloid-derived suppressor cells","volume":"192","author":"Ballbach","year":"2017","journal-title":"Immunol. Lett."},{"issue":"9","key":"10.1016\/j.intimp.2022.109442_b0230","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/bjc.2015.101","article-title":"IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer","volume":"112","author":"Abiko","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"19","key":"10.1016\/j.intimp.2022.109442_b0235","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.intimp.2022.109442_b0240","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1084\/jem.20160801","article-title":"PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity","volume":"214","author":"Juneja","year":"2017","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.intimp.2022.109442_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101085","article-title":"A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory\/relapsed B cell lymphoma","volume":"14","author":"Liu","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.intimp.2022.109442_b0250","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.745286","article-title":"Engineered Removal of PD-1 From the Surface of CD19 CAR-T Cells Results in Increased Activation and Diminished Survival","volume":"8","author":"Kalinin","year":"2021","journal-title":"Front. Mol. Biosci."},{"issue":"10","key":"10.1016\/j.intimp.2022.109442_b0255","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1111\/cas.14169","article-title":"Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells","volume":"110","author":"Nakajima","year":"2019","journal-title":"Cancer Sci."},{"issue":"24","key":"10.1016\/j.intimp.2022.109442_b0260","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.intimp.2022.109442_b0265","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","article-title":"A human memory T cell subset with stem cell-like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.intimp.2022.109442_b0270","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.intimp.2022.109442_b0275","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrc3774","article-title":"The tumour microenvironment in B cell lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.intimp.2022.109442_b0280","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40364-020-00190-8","article-title":"Biomarkers in individualized management of chimeric antigen receptor T cell therapy","volume":"8","author":"Du","year":"2020","journal-title":"Biomark Res."},{"issue":"8","key":"10.1016\/j.intimp.2022.109442_b0285","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J. Clin. Invest."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922009274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922009274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:46:03Z","timestamp":1761587163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922009274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":57,"alternative-id":["S1567576922009274"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109442","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109442","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109442"}}